Eculizumab

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.
Read more
€0.00 (tax incl.)
Reference:
HY-P9914
Product Details
HY-P9914

Data sheet

Size
Multiple sizes
Reactivity
Complement System
Application
Neuroscience-Neuromodulation
CAS
219685-50-4

Menu

Settings